Solute carrier transporter superfamily member SLC16A1 is a potential prognostic biomarker and associated with immune infiltration in skin cutaneous melanoma

References

• Tai W, Gao X. Noncovalent tagging of siRNA with steroids for transmembrane delivery. Biomaterials. 2018;178:720–727.
   PubMed Web of Science ®Google Scholar
• Ma S. Membrane transporter research in times of countless structures. Biochim Biophys Acta Biomembr. 2018;1860(4):804–808.
   PubMed Web of Science ®Google Scholar
• Me M, Rodriguez-Cruz V, Felmlee MA, et al. SLC and ABC transporters: expression, Localization, and species differences at the blood-brain and the blood-cerebrospinal fluid barriers. AAPS J. 2017;19(5):1317–1331.
   PubMed Web of Science ®Google Scholar
• Amawi H, Sim HM, Tiwari AK, et al. ABC transporter-mediated multidrug-resistant cancer. Adv Exp Med Biol. 2019;1141:549–580.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang J. Targeting uptake transporters for cancer imaging and treatment. Acta Pharm Sin B. 2020;10(1):79–90.
   PubMed Web of Science ®Google Scholar
• Ya B, Costales C, Mathialagan S, et al. Quantitative contribution of six major transporters to the hepatic uptake of drugs: “SLC-Phenotyping” using primary human hepatocytes. [published correction appears in J pharmacol exp ther. J Pharmacol Exp Ther. 2019;370(1):72–83. 2020 Mar;372(3):354].
   PubMed Web of Science ®Google Scholar
• Ww W, Gallo L, Jadhav A, et al. The druggability of solute carriers. J Med Chem. 2020;63(8):3834–3867. .
   PubMed Web of Science ®Google Scholar
• Zimmermann I, Egloff P, Hutter CA, et al. Synthetic single domain antibodies for the conformational trapping of membrane proteins. Elife. 2018;7:e34317. . Published 2018 May 24.
   PubMed Web of Science ®Google Scholar
• Liu X. SLC family transporters. Adv Exp Med Biol. 2019;1141:101–202.
   PubMed Web of Science ®Google Scholar
• Liu X. Transporter-mediated drug-drug interactions and their significance. Adv Exp Med Biol. 2019;1141:241–291.
   PubMed Web of Science ®Google Scholar
• MJ W, Vignali PDA, Mullett SJ, et al. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature. 2021;591(7851):645–651. .
   PubMed Web of Science ®Google Scholar
• Schadendorf D, ACJ VA, Berking C, et al. Melanoma [published correction appears in lancet. Lancet. 2018;392(10151):971–984. . 2019 Feb 23;393(10173):746].
   PubMed Web of Science ®Google Scholar
• International Agency for Research on Cancer, WHO. GLOBOCAN 2012: estimated cancer incidence, mortality, and prevalence worldwide in 2012. 2013. http://globocan.iarc.fr.
   Google Scholar
• Schadendorf D, Fisher DE, Garbe C, et al. Melanoma. Nat Rev Dis Primers. 2015;1:15003. Published 2015 Apr 23.
   PubMed Web of Science ®Google Scholar
• Dr R, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6(1):1–6.
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102. .
   PubMed Web of Science ®Google Scholar
• DS C, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–658.
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. Published 2013 Apr 2.
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Morris JH, Cook H, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45(D1):D362–D368. .
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110.
   PubMed Web of Science ®Google Scholar
• Schwartz L, Supuran CT, Alfarouk KO, et al. The warburg effect and the hallmarks of cancer. Anticancer Agents Med Chem. 2017;17(2):164–170. .
   PubMed Web of Science ®Google Scholar
• Vander HMG, Cantley LC, Thompson CB, et al. Understanding the warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033. .
   PubMed Web of Science ®Google Scholar
• Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell. 2008;13(6):472–482.
   PubMed Web of Science ®Google Scholar
• Tasdogan A, Faubert B, Ramesh V, et al. Metabolic heterogeneity confers differences in melanoma metastatic potential. Nature. 2020;577(7788):115–120. .
   PubMed Web of Science ®Google Scholar
• Ia C. Cancer biology. Methods Mol Biol. 2011;731:1–11.
   PubMedGoogle Scholar
• Faratian D, Bown JL, Smith VA, et al. Cancer systems biology. Methods Mol Biol. 2010;662:245–263.
   PubMedGoogle Scholar
• Ma D, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12–27.
   PubMed Web of Science ®Google Scholar
• Balaji V, Pokrzywa W, Hoppe T, et al. Ubiquitylation pathways in insulin signaling and organismal homeostasis. Bioessays. 2018;40(5):e1700223. .
   PubMed Web of Science ®Google Scholar
• Popovic D, Vucic D, Dikic I, et al. Ubiquitination in disease pathogenesis and treatment. Nat Med. 2014;20(11):1242–1253. .
   PubMed Web of Science ®Google Scholar
• Rape M. Ubiquitylation at the crossroads of development and disease. Nat Rev Mol Cell Biol. 2018;19(1):59–70.
   PubMed Web of Science ®Google Scholar
• Sa W, Beli P, Weinert BT, et al. A proteome-wide, quantitative survey of in vivo ubiquitylation sites reveals widespread regulatory roles. Mol Cell Proteomics. 2011;10(10):M111.013284. .
   Web of Science ®Google Scholar
• Fan Y, You G. Proteasome inhibitors bortezomib and carfilzomib stimulate the transport activity of human organic anion transporter 1. Mol Pharmacol. 2020;97(6):384–391.
   PubMed Web of Science ®Google Scholar
• Katsuya K, Oikawa D, Iio K, et al. Small-molecule inhibitors of linear ubiquitin chain assembly complex (LUBAC), HOIPINs, suppress NF-κB signaling. Biochem Biophys Res Commun. 2019;509(3):700–706. .
   PubMed Web of Science ®Google Scholar
• Wang Z. ErbB receptors and cancer. Methods Mol Biol. 2017;1652:3–35.
   PubMedGoogle Scholar
• Sasidharan NV, Elkord E. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells [published correction appears in immunol cell biol. Immunol Cell Biol. 2018;96(1):21–33. 2018 Feb;96(2):236].
   PubMed Web of Science ®Google Scholar
• Burugu S, Asleh-Aburaya K, Nielsen TO, et al. Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. Breast Cancer. 2017;24(1):3–15. .
   PubMed Web of Science ®Google Scholar
• Bc C, Vucic S, Krishnan AV, et al. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem. 2010;17(18):1942-199.
   Web of Science ®Google Scholar
• Hu G, Henke A, Karpowicz RJ Jr, et al. New fluorescent substrate enables quantitative and high-throughput examination of vesicular monoamine transporter 2 (VMAT2). ACS Chem Biol. 2013;8(9):1947–1954. .
   PubMed Web of Science ®Google Scholar
• Lin L, Yee SW, Kim RB, et al. SLC transporters as therapeutic targets: emerging opportunities. Nat Rev Drug Discov. 2015;14(8):543–560.
   PubMed Web of Science ®Google Scholar